CASI Pharmaceuticals, Inc. (CASI) Earnings History
Net Loss31 years of earnings data (1994–2024) · Currently unprofitable on a TTM basis
Loading earnings history...
CASI Pharmaceuticals, Inc. (CASI) Earnings Overview
As of June 23, 2026, CASI Pharmaceuticals, Inc. (CASI) reported trailing twelve-month net income of -$49M, reflecting -26.7% year-over-year growth. The company earned $-3.08 per diluted share over the past four quarters, with a net profit margin of -137.6%.
Looking at the long-term picture, CASI's historical earnings data spans multiple years. The company achieved its highest annual net income of -$5M in fiscal 2011.
CASI Pharmaceuticals, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including ZLAB (-$178M net income, -38.1% margin), LEGN (-$250M net income, -28.8% margin), ZYME (-$103M net income, -76.6% margin), CASI has room to improve margins relative to the peer group. Compare CASI vs ZLAB →
CASI Earnings vs Peers
Earnings metrics vs comparable public companies
CASI Historical Earnings Data (1994–2024)
31 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$39M | -45.7% | -$40M | $-2.56 | -137.6% | -138.8% |
| 2023 | -$27M | +34.3% | -$25M | $-2.02 | -79.5% | -74.0% |
| 2022 | -$41M | -11.9% | -$26M | $-3.01 | -95.1% | -61.5% |
| 2021 | -$37M | +24.1% | -$42M | $-2.69 | -121.5% | -137.6% |
| 2020 | -$48M | -6.4% | -$53M | $-4.37 | -318.9% | -348.6% |
| 2019 | -$45M | -65.1% | -$40M | $-4.80 | -1098.1% | -968.1% |
| 2018 | -$27M | -155.1% | -$27M | $-3.24 | - | - |
| 2017 | -$11M | -13.9% | -$11M | $-1.75 | - | - |
| 2016 | -$9M | -31.2% | $9M | $-1.69 | - | - |
| 2015 | -$7M | +72.5% | $7M | $-2.22 | -15104.0% | 14990.8% |
| 2014 | -$26M | -356.6% | $26M | $-9.16 | -110432.5% | 110370.0% |
| 2013 | -$6M | +60.5% | $6M | $-2.20 | - | - |
| 2012 | -$15M | -219.1% | $5M | $-7.63 | -2173.2% | 672.9% |
| 2011 | -$5M | +43.7% | -$5M | $-3.87 | -234.9% | -235.4% |
| 2010 | -$8M | +1.4% | -$5M | $-8.37 | -219.4% | -122.8% |
| 2009 | -$8M | +65.6% | $7M | $-10.30 | -155.5% | 127.2% |
| 2008 | -$24M | -6.5% | $22M | $-30.35 | -319.1% | 299.0% |
| 2007 | -$22M | +55.1% | $24M | $-29.29 | -303.0% | 320.9% |
| 2006 | -$50M | -205.8% | $52M | $-76.35 | -723.6% | 749.2% |
| 2005 | -$16M | -29.2% | $17M | $-37.25 | -275.7% | 292.8% |
| 2004 | -$13M | +35.3% | $17M | $-37.35 | -2455.6% | 3225.7% |
| 2003 | -$19M | +50.0% | $20M | $-71.61 | -1237.3% | 1250.3% |
| 2002 | -$39M | +9.9% | $44M | $-196.07 | -3316.8% | 3745.4% |
| 2001 | -$43M | +11.2% | $67M | $-263.30 | -2326.0% | 3588.3% |
| 2000 | -$49M | -32.2% | $51M | $-334.27 | -1328.9% | 1381.3% |
| 1999 | -$37M | -173.3% | -$39M | $-294.11 | -738.0% | -770.0% |
| 1998 | -$14M | -107.7% | $16M | $-117.10 | -259.6% | 301.9% |
| 1997 | -$7M | -35.4% | -$9M | $-59.40 | -135.4% | -189.6% |
| 1996 | -$5M | +37.7% | $7M | $-53.90 | -109.1% | 150.0% |
| 1995 | -$8M | -50.6% | -$8M | $-15.42 | -1070.8% | -1068.1% |
| 1994 | -$5M | - | -$5M | $-6.10 | -5688.9% | -5700.0% |
Download Data
Export CASI earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
32+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
CASI — Frequently Asked Questions
Quick answers to the most common questions about buying CASI stock.
What is CASI earnings per share (EPS)?
CASI trailing twelve-month (TTM) diluted EPS is $-3.08, reflecting -26.7% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 1994 to 2024 is available in the table on this page.
What is CASI Pharmaceuticals, Inc.'s net income?
CASI Pharmaceuticals, Inc. (CASI) trailing twelve-month net income is $-49M as of 2024. Earnings declined -26.7% year-over-year.
Is CASI profitable?
CASI is not currently profitable on a TTM basis, reporting a net loss of $-49M. Net margin is -137.6%. Investors should monitor for a return to profitability.
What is CASI's earnings growth rate?
CASI compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 1994 to 2024.
What are CASI's profit margins?
CASI Pharmaceuticals, Inc. net profit margin is -137.6%, operating margin is -138.8%, and gross margin is +39.1%. Below-average margins reflect competitive or cost pressures. Return on Equity is -301.8%.
Is CASI growing earnings?
CASI earnings are declining — EPS fell -26.7% year-over-year. TTM net income dropped to $-49M. This contrasts with the 5-year CAGR of N/A.
What was CASI's best earnings year?
CASI Pharmaceuticals, Inc.'s highest annual net income on record is $-5M, achieved in fiscal year 2011. Earnings history on this page spans 1994 to 2024 and includes all annual and quarterly figures.
What were CASI's earnings last quarter?
CASI's most recent reported quarter was Q3 2025. Net income was $-11M with diluted EPS of $-0.68. For a full breakdown of all quarters, see the quarterly earnings table on this page.